Abstract:CXCR3 is a CXC chemokine receptor that, together with its three major ligands, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC), is involved in inflammatory responses, mediated mainly by T cells. In several immune-related diseases, including chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), rheumatoid arthritis, multiple sclerosis, and atherosclerosis, CXCR3 and/or its ligands are found to be overexpressed, potentially indicating a role for this receptor in these diseases. Animal models have confirmed the therapeutic potential of targeting CXCR3 in the treatment of such diseases. Several peptidic, peptidomimetic, and small non-peptidomimetic CXCR3 ligands have been disclosed in the past 10 years. These ligands have served as chemical tools for the investigation of CXCR3 activation, blocking, and signaling, and some of these ligand series have been developed as potential therapeutic agents against inflammation. Computational modeling studies, facilitated by the recent developments in GPCR structural biology, together with mutagenesis and pharmacological studies, have aided in understanding how these ligands interact with CXCR3.This chapter will give an overview on how the combination of these chemical, computational, and pharmacological tools and techniques has increased our understanding of the molecular mechanisms by which small-molecule antagonists and agonists bind to CXCR3 compared to the relatively large chemokines. A detailed overview of CXCR3 ligand structure-activity relationships and structure-function relationships will be presented. This comparative analysis reveals that the full spectrum of antagonist and agonist effects on CXCR3 is now within reach by appropriate scaffolds and chemical modifications. Many of these ligands display behavior deviating from simple competition and do not interact with the chemokine binding site, providing evidence for an allosteric mode of action. Moreover, the computer-assisted molecular modeling of CXCR3 receptor-ligand interactions is discussed in view of GPCR crystal structures and mutagenesis studies of CXCR3 and other chemokine receptors. Improved insights in the interplay between CXCR3-ligand interactions and CXCR3-mediated signaling pathways potentially open up novel therapeutic opportunities in the area of inflammation.

The Chemical Diversity and Structure-Based Evolution of Non-Peptide CXCR4 Antagonists with Diverse Therapeutic Potential.

Structure-Based Development of Antagonists for Chemokine Receptor CXCR4

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs

Discovery of Non-Peptide Small Molecular Cxcr4 Antagonists As Anti-Hiv Agents: Recent Advances and Future Opportunities

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

Design, Synthesis, and Structure-Activity-relationship of a Novel Series of CXCR4 Antagonists.

Progress in Studies of Structure, Mechanism and Antagonists Interaction of GPCR Co-Receptors for HIV.

Design, Synthesis, and Evaluation of Novel CXCR4 Antagonists Based on an Aminoquinoline Template.

Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists

Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines

Clinical Significance of Chemokine Receptor Antagonists

Structural Basis of the Interactions Between Cxcr4 and Cxcl12/Sdf-1 Revealed by Theoretical Approaches

Structural insights into the activation and inhibition of CXC chemokine receptor 3

Computational Analysis of the Structural Mechanism of Inhibition of Chemokine Receptor CXCR4 by Small Molecule Antagonists

Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.

Exploring the CXCR3 Chemokine Receptor with Small-Molecule Antagonists and Agonists

Exploring the Stereochemistry of CXCR4-peptide Recognition and Inhibiting HIV-1 Entry with D-peptides Derived from Chemokines.

CXCR3-binding chemokines: novel multifunctional therapeutic targets

Molecular Dynamics Insights into the Selectivity Toward CXCR1 and CXCR2 Antagonists

Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Discovery of 1,5-Dihydro-4<i>H</i>-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2